DCAT Value Chain Insights Podcast

Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important barometer of the financial health of the sectors, has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?Featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)Support the show

As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains.  Support the show

What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains. Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan AssociatesSupport the show

How are supply and demand shaping up for sterile manufacturing and aseptic fill–finish in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such as GLP-1 agonist impact market fundamentals.   Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals, vaccines, and leads L.E.K.'s Pharmaceutical Contract Services practice. Support the show

What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI.  Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLPSupport the show

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) Major trends in parenteral drug development Long peptides in NDAs and BLAs New complex modalities Sterile drug-product capacity market shifts Complex sterile injectables Regulatory issues Digitalization and automation Podcast Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show  Support the show

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterSamsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza CambrexExpansions in peptides, oligonucleotides BachemAgilent TechnologiesWuXi STACordenPharmaAjinomotoBain's acquisition of F.I.S.eureKINGNew CDMOs enter the market Bridgewest Group SynCrest NewBiologix Ascend Gene & Cell Therapies Podcast Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show  Support the show

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry's radar. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterLarge-scale biomanufacturing expansions continue Samsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza WuXi BiologicsExpansions in Peptides and Oligonucleotides Ramp UpBachemAgilent TechnologiesWuXi STACordenPharmaNew CDMOs Enter the Market eureKINGNewBiologixAscend Gene & Cell TherapiesPodcast Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show  Support the showSupport the show

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) Proposed reforms Security of supply and supply-chain reforms Specific proposals Podcast Sponsor: BIOVECTRALinks: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @DCATvci Support the show  Support the show

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Recent expansion projects Baxter BioPharma Solutions Vetter Recipharm WuXi STA Jubilant HollisterStier PCI Pharma Services Grand River Aseptic Manufacturing Catalent Thermo Fisher Scientific Lonza  Carbogen Amcis Alcami Delpharm Fareva WuXi Biologics IDT Biologika Emergent CDMO  BSP Pharmaceuticals Aenova Samsung Biologics  Ajinomoto Bio-Pharma Services Selkirk Pharma INCOG BioPharma Services ten23 health Berkshire Sterile Manufacturing Sponsor: Vetter Pharma International GmbH  Links: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @DCATvci Support the show  Support the show

What are noteworthy trends in drug delivery and drug-product development in key dosage forms: solid dosage and parenteral drugs? A look at key technology advances and recent new drug approvals. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Recent trends: new drug approvalsTechnology advancesEnable Injections' on-body subcutaneous drug-delivery systemLilly's and Triastek's pact for 3-D printing for oral drug deliveryMultifunctional wireless robots in drug deliveryAdvances in implantable devices for drug delivery Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show Support the show

Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)A roundup of recent investments in HPAPI manufacturing WuXi STA MilliporeSigmaPiramal Pharma SolutionsCambrexHAS Healthcare Advanced SynthesisAGC Fine ChemicalsLonzaCarbogen AmcisSterling Pharma SolutionsAjinomoto Bio-Pharma ServicesNovasepOlonCerbios-PharmaFormosa LaboratoriesSai Life SciencesBSP PharmaceuticalsSeqensCordenPharma Sponsor: BIOVECTRA Links:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show Support the show

A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Sustainability and the bio/pharma supply chainKey finding: External stakeholders drive effortsKey finding: Supply-chain sustainability lags internal effortsKey finding: Measuring achievement a major challengeKey finding:  Factoring sustainability into purchasing decisions Concluding thoughtsSponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show Support the show (https://dcat.org/MemberApplication.htm)

Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)A roundup of expansion activityFujifilm Diosynth BiotechnologiesSamsung BiologicsLonzaBoehringer IngelheimThermo Fisher ScientificCatalentWuXi Biologics Sponsor: BIOVECTRALinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show Support the show (https://dcat.org/MemberApplication.htm)

A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Supply-chain challenges and solutions (1:13)Sponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the showSupport the show (https://dcat.org/MemberApplication.htm)

Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Active area of investment (1:13)Baxter BioPharma Solutions (1:25)PCI Pharma Services (2:07)Alcami (3:22)Catalent (4:31)Vetter (5:47)Thermo Fisher Scientific (6:41)Grand River Aseptic Manufacturing (7:35)Lonza (9:12)Curia (9:50)Jubilant HollisterStier (10:22)Carbogen Amcis (10:53)Fareva (11:46)BSP Pharmaceuticals (12:43)Recipharm (13:33)Aenova (15:01)Wuxi Biologics (15:42)Samsung Biologics (16:08)Ajinomoto Bio-Pharma Services (16:44)Selkirk Pharma (17:07)Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What's the plan?Key topics: (see Chapter Markers)Economic recovery brings pricing pressuresRising energy costs and the bio/pharma manufacturing value chain Rising energy costs: call for action in the EU Ripple effect throughout industrial supply chainsActions proposed by the European CommissionProposals for energy-price reliefSponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Modality of top-selling productsNew drug approvals: small molecules versus biologicsPotential blockbusters: small molecules and biologicsBiogen's and Eisai's aducanumabArgenx's efgartigimodBristol-Myers Squibb's mavacamtenUCB's bimekizumabBristol Myers Squibb's/bluebird bio's idecabtagene vicleucel (ide-cel)Ascendis Pharma's TransCon hGH (lonapegsomatropin)Sponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

Drug delivery is important not only for ensuring bioavailability for therapeutic benefit but also for product differentiation and market success. DCAT Value Chain Insights highlights technology advances in drug delivery for injectable and solid-dosage drugs and other products from recent start-ups, partnering deals, and mergers and acquisitions. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Mergers and acquisitionsPartneringStart-upsNew strategy/managementSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

What have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)CDMOs and COVID-19 vaccine manufacturingPotential implications of increased injectables capacityCDMO M&A remains robustCell and gene therapies: a major source of CDMO M&APrivate equity and CDMO M&ALargest deal thus far: Thermo Fisher Scientific/PPDSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

FDA Addresses Supply Constraints Due to COVID-19; Plus, Packaging Suppliers Expand In this podcast we take a look at the FDA's new guidance to facilitate changes to container-closure-system components due to supply constraints, plus updates from suppliers of materials used to deliver COVID-19 vaccines, treatments and other parenteral drugs. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)FDA addresses supply constraintsSuppliers increase production Sponsor: Vetter Pharma International GmbH Links:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

Although the COVID-19 pandemic dominated the headlines  in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)2020 in Review: The Top 10 Developments1.      Volume growth of pharmaceuticals declines globally.2.      New molecular entities approvals by FDA keeps pace with prior years.3.      The new AbbVie: AbbVie's $63-Bn acquisition of Allergan.4.      Viatris  launches as new company: Mylan plus Upjohn, Pfizer's off-patent branded and generic established medicines business.5.      Gilead Sciences' $21-Bn acquisition of Immunomedics6.      Danaher's $21.4-Bn acquisition of GE Healthcare Life Sciences and launch of Cytiva. 7.      Merck & Co.'s pending spin-off of women's health, biosimilars & legacy products to form a new company.8.      Reshoring drug manufacturing gains policy momentum.9.      Some drug pricing reforms in the US move forward10.   Brexit uncertainty still looms.Sponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer's off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Rationale for the new companyInside the new Viatris: productsInside the new Viatris: manufacturingInside Viatris: leadership, company structure, and cost-savings planSponsor: LabVantage SolutionsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)New drug approvals and solid-dosage productsCDMOs/CMOs: inside the numbersRecent facility acquisitions among solid-dose CDMOs/CMOsOther expansionsCatalentLonzaMetrics Contract ServicesNextPharmaThermo Fisher ScientificLGM PharmaFrontida BioPharmAdare PharmaceuticalsCoreRxVelesco PharmaUpperton Pharma SolutionsSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Pharma CEOs to watch in 20201. Three-way tie: Pfizer, J&J, and AstraZeneca.Pfizer Chairman and CEO Albert BourlaJ&J Chairman and CEO Alex GorskyAstraZeneca CEO Pascal Soriot4. Moderna CEO Stéphane Bancel5. Gilead Sciences Chairman and CEO Daniel O'Day6. Regeneron Pharmaceuticals Co-Founder, President and CEO Leonard S. Schleifer7 (tie). CureVac CEO Franz-Werner Haas and Novavax CEO and President Stanley C. Erck9. Seagen (formerly Seattle Genetics) President, CEO and Chairman Clay Siegall10. Genmab CEO Jan G. J. van de WinkelSponsor: LabVantage SolutionsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside Big Pharma's pipelineAbbVieAmgen/AstraZenecaAstraZenecaBristol-Myers SquibbEli Lilly and CompanyGlaxoSmithKlineRocheSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature a roundup of up expansions by CDMOs/CMOs and other suppliers in injectable drug development and manufacturing. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Injectable drugs and recent drug approvalsManufacturing expansions and technology advancesA roundup of CDMO/CMO expansions thus far in 2020VetterCatalentGrand River Aseptic ManufacturingCordenPharmaAlcamiThermo Fisher ScientificRecipharmSamsung BiologicsPCI Pharma ServicesWuXi BiologicsBushu PharmaceuticalsEvonikLSNE Contract ManufacturingBerkshire Sterile ManufacturingIntegrity BioArgonaut Manufacturing ServicesSuppliers of packaging materials and components for injectable drugs expandCorningStevanato GroupSchottWest Pharmaceutical ServicesSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)Support the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Small-molecule new drug approvals thus far in 2020Small molecules and blockbuster potentialNovo Nordisk's RybelsusBristol-Myers Squibb's Zeposia  Novartis' inclisiranGilead Sciences' filgotinib  Akebia  Therapeutics', Mitsubishi Tanabe Pharma's, and Otsuka Pharmaceutical's vadadustat  Biohaven Pharmaceuticals' Nurtec Sponsor: Dr. Reddy's LaboratoriesLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature the top 10 deals thus far in 2020 and which pharma/biopharma companies are rising to the top. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)1. Novartis's $9.7-billion acquisition of The Medicines Company and Blackstone's $2-billion investment in Alnylam  Pharmaceuticals.2. Daiichi Sankyo's  and AstraZeneca's $6-billion ADC collaboration. Pairing3. Gilead Sciences' $4.9-billion acquisition of Forty Seven Inc.4. Genmab's $3.9-billion cancer antibody pact with AbbVie.5. Sanofi's pending $3.69-billion acquisition of Principia Biopharma.6. Amgen's $3.2-billion combined deals with BeiGene .7. Astellas's $3-billion acquisition of Audentes Therapeutics.8. Sangamo Therapeutics' $2.7-billion licensing pact with Biogen.9. Merck & Co's $2.7-billion acquisition of ArQule .10 (Tie): Merck & Co.'s $2.5-billion research pacts with Taiho  Pharmaceutical and Astex Pharmaceuticals, subsidiaries of Otsuka .10 (Tie): Sanofi 's $2.5-billion acquisition of Synthorx .  Sponsor: LabVantage SolutionsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that outlines the FDA's proposed pilot program for the evaluation of novel excipients and summarizes industry feedback on the review program. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Novel excipients and the FDAFDA's view of a possible novel excipient review pilot programIndustry feedbackLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSponsor: LabVantage SolutionsSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)A plan for addressing supply-chain vulnerabilities in the USLegislative proposals in the USLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that explores the future of digital medicines. For a text version of this article, visit dcatvci.org.Key topics: (see Chapter Markers)Digital medicines and digital healthDigital health and digital medicines: a market viewPharma industry and digital health and digital medicinesLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature DCAT Value Chain Insights' Top 10 Emerging Pharma Watch List based on recent high-value partnering deals. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Emerging pharma strength1.      Roivant Sciences2.      Sangamo Therapeutics3.      Silence Therapeutics4.      Innovent Biologics5.      Arcus Biosciences6.      MorphoSys7.      Evox Therapeutics8.      Accent Therapeutics9.      Enleofen Bio10.   SitryxLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects.  For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)The CDMO industry in the wake of COVID-19Near-term outlookMedium-term could be challengingLonger-term implicationsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we round up key recent expansions in high-potency manufacturing by CDMOs and CMOs. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Expansions in high-potency manufacturingLonzaWuXi AppTecSeqensCambrexPiramal Pharma SolutionsCordenPharmaFlammaCerbios-PharmaEvonikAGCNovasepAjinomoto Bio-Pharma ServicesBSP PharmaceuticalsPCI Pharma ServicesSterling Pharma SolutionsHeraeusProcosLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Examining trade-related risksStudy's backgroundSources of supply-chain riskAwareness of supply-chain riskManaging supply-chain risksUS market scenariosVulnerable industry supply chainsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we feature an article that examines the new AbbVie, including the key products and expanded manufacturing networking, resulting from its recent acquisition of Allergan.  For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the dealInside the new AbbVieLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we feature an article about the Association for Accessible Medicines' blueprint to facilitate a repatriation of pharma manufacturing to the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)A plan for re-inventing the US pharma supply chainsA proposal for increasing US-based manufacturing for high-priority medicinesList of essential medicines and assessment of the supply chainIncentives for securing the US pharma supply chainLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we outline the manufacturing strategies and alliances that are in play to develop and supply treatments and vaccines against COVID-19? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the numbers: tracking potential treatments and vaccinesSupply lines for potential COVID-19 drugs and vaccinesThe supply lines: vaccinesRamping up production for potential COVID-19 drugsSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals.  For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Drug development and regulatory reviewFDA's perspectiveNew drug approvals thus far in 2020Clinical trials and COVID-19: where the impact residesCompanies adjust clinical-trial research strategiesSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast we feature DCAT Value Chain Insights' Top 10 Watch List for Biologics and Biomanufacturing.  For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Vaccines: the race for a vaccine against the novel coronavirus.Vaccine manufacturing: technology and scale-up.Biologic-based antivirals against the novel coronavirus.Head of the class: the top-selling biologics.Biologics' share of new drug approvals.Biosimilars: new market entrants.Biosimilars and interchangeability: the market impact.Cell and gene therapies: manufacturing investments.Advances in biomanufacturing.Live biotherapeutic products: a new opportunity.  Sponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

What measures are being taken by European Union authorities to mitigate potential shortages stemming from supply-chain and manufacturing disruptions?  In this podcast we feature an article that outlines the guidance issued by EU authorities to provide flexibility in sourcing for crucial medicines for the treatment of COVID-19. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Providing regulatory flexibility for sourcing activitiesThe exceptional change-management processOther measures in the EU to mitigate drug shortagesSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

What impact is COVID-19 having on pharmaceutical supply chains? In this podcast, we feature an article that reports on the concerns raised by industry groups, including reduced availability of international air transportation and increasing costs for shipping medicines into the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Industry groups weigh in on supply-chain concernsInternational air transportation availability and costsRepatriation of pharmaceutical manufacturing back to the USPotential supply disruptions of drugs identified as potential treatments against COVID-19Prescription refills Sponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

In this podcast, we feature an article that looks at the Indian government's $1.3-billion multi-year plan to increase domestic production of key starting materials and active pharmaceutical ingredients and its potential impact on global supply chains. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)India and pharmaceuticals: short termIndia and pharmaceuticals: longer termSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

What does the global nature of the pharmaceutical supply chain mean for US policy? In this podcast, we feature an article that looks at proposals from members of Congress and the federal government to incentivize domestic drug manufacturing in the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Global pharmaceutical supply chainsProposals for encouraging US-based pharmaceutical manufacturingOther legislative proposalsExecutive actionSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

What are the new blockbuster medicines to watch? In this podcast we feature an article that examines the eleven medicines projected to enter the market in 2020 and achieve blockbuster status by 2024, according to a recent analysis by Clarivate Analytics' Cortellis Forecast Team. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Blockbuster watch: Big PharmaNovo Nordisk's Rybelsus (semaglutide)AstraZeneca's and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki)Immunomedics' sacituzumab govitecanBristol-Myers Squibb's liso-cel (or lisocabtagene maraleucel),Bristol-Myers Squibb's ozanimodNovartis' ofatumumab (subcutaneous)Novartis' inclisiranGilead Sciences' filgotinibAkebia Therapeutics', Mitsubishi Tanabe Pharma's, and Otsuka Pharmaceutical's vadadustatBioMarin Pharmaceutical's ValroxBiohaven Pharmaceuticals' rimegepantSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

Over the past several years, orphan drugs have accounted for more than 40% of new drug approvals by the FDA.  In this podcast, we showcase an article that explores whether they are producing the revenue gains pharma companies are seeking or if they are too niche? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside new drug approvals and drug-development trends for orphan drugsInside the market for orphan drugsMarket outlook for orphan drugsOrphan-drug NMEs and market penetrationSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

To what extent do emerging pharma companies contribute to the pharmaceutical industry's pipeline and new product growth? In this podcast, we showcase an article examining a recent report by IQVIA that analyzes emerging bio pharma companies' contribution to innovation. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the numbersInside emerging biopharma companiesEmerging biopharma companies and larger companiesEmerging biopharma companies and therapeutic focusEmerging biopharma companies and commercial productsSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)

The conditions are favorable for another strong year of performance for CDMOs. In this podcast, we showcase an article written by Jim Miller, Consultant and Content Advisor at DCAT, that examines industry fundamentals and an outlook for pharma outsourcing in 2020. For the text version of this article go to dcatvci.org.Key topics: (see Chapter Markers)Strong fundamentals but some risk   Mergers and acquisitions: what may be ahead  Big Pharma restructuring  Upbeat outlook   Sponsor: CordonPharmaLinks:Subscribe to our e-newsletter at dcatvci.orgFollow us on Twitter @DCATvciSupport the show (https://dcat.org/MemberApplication.htm)